Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ACE | P12821 | 8/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8640334 | 1.00 | REN (0.56) | RENSMN1; SMN2ACELMNAMME | |
| SCHEMBL5870272 | 1.00 | REN (0.56) | RENSMN1; SMN2ACELMNAMME | |
| Hydrochloric Acid SCHEMBL10703732 | 0.99 | REN (0.56) | RENSMN1; SMN2ACELMNAMME | |
| Hydrochloric Acid SCHEMBL10703729 | 0.99 | REN (0.56) | RENSMN1; SMN2ACELMNAMME | |
| SCHEMBL8257832 | 0.91 | REN (0.56) | RENSMN1; SMN2ACELMNAABCB11 | |
| SCHEMBL8435225 | 0.91 | REN (0.56) | RENSMN1; SMN2ACELMNAABCB11 | |
| SCHEMBL8248581 | 0.89 | MME (0.62) | ACEMME | |
| SCHEMBL8248814 | 0.89 | MME (0.62) | ACEMME | |
| SCHEMBL8249153 | 0.89 | MME (0.62) | ACEMME | |
| SCHEMBL8248719 | 0.89 | MME (0.62) | ACEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| EP-0243645-B1 | Compounds having a nootropic activity, agents containing them and their use in the treatment and prophylaxis of cognitive malfunctions | HOECHST AG (DE) | 1994-03-16 | — | — | EP | disclosed |
| US-5231084-A | ACE inhibitor | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-07-27 | — | — | US | disclosed |
| EP-0243645-A2 | Compounds having a nootropic activity, agents containing them and their use in the treatment and prophylaxis of cognitive malfunctions | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | REN 7/4885SMN1; SMN2 3028/4885ACE 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.